![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CXCR2 |
Gene summary for CXCR2 |
![]() |
Gene information | Species | Human | Gene symbol | CXCR2 | Gene ID | 3579 |
Gene name | C-X-C motif chemokine receptor 2 | |
Gene Alias | CD182 | |
Cytomap | 2q35 | |
Gene Type | protein-coding | GO ID | GO:0001525 | UniProtAcc | P25025 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
3579 | CXCR2 | HCC1 | Human | Liver | HCC | 1.08e-08 | 8.70e-01 | 0.5336 |
3579 | CXCR2 | HCC2 | Human | Liver | HCC | 7.41e-12 | 9.57e-01 | 0.5341 |
3579 | CXCR2 | HCC5 | Human | Liver | HCC | 1.90e-09 | 1.64e+00 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000226222 | Liver | HCC | myeloid cell homeostasis | 93/7958 | 157/18723 | 1.67e-05 | 1.81e-04 | 93 |
GO:004311221 | Liver | HCC | receptor metabolic process | 96/7958 | 166/18723 | 4.69e-05 | 4.50e-04 | 96 |
GO:000689821 | Liver | HCC | receptor-mediated endocytosis | 134/7958 | 244/18723 | 5.73e-05 | 5.31e-04 | 134 |
GO:004887222 | Liver | HCC | homeostasis of number of cells | 147/7958 | 272/18723 | 7.48e-05 | 6.70e-04 | 147 |
GO:003090121 | Liver | HCC | midbrain development | 54/7958 | 90/18723 | 6.04e-04 | 3.79e-03 | 54 |
GO:00016553 | Liver | HCC | urogenital system development | 170/7958 | 338/18723 | 2.15e-03 | 1.08e-02 | 170 |
GO:00018222 | Liver | HCC | kidney development | 148/7958 | 293/18723 | 3.25e-03 | 1.49e-02 | 148 |
GO:00720012 | Liver | HCC | renal system development | 152/7958 | 302/18723 | 3.45e-03 | 1.56e-02 | 152 |
GO:00025262 | Liver | HCC | acute inflammatory response | 62/7958 | 112/18723 | 4.06e-03 | 1.77e-02 | 62 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0414422 | Liver | HCC | Endocytosis | 178/4020 | 251/8465 | 2.03e-14 | 5.22e-13 | 2.91e-13 | 178 |
hsa051202 | Liver | HCC | Epithelial cell signaling in Helicobacter pylori infection | 50/4020 | 70/8465 | 3.96e-05 | 2.16e-04 | 1.20e-04 | 50 |
hsa0516322 | Liver | HCC | Human cytomegalovirus infection | 131/4020 | 225/8465 | 6.86e-04 | 2.77e-03 | 1.54e-03 | 131 |
hsa0414432 | Liver | HCC | Endocytosis | 178/4020 | 251/8465 | 2.03e-14 | 5.22e-13 | 2.91e-13 | 178 |
hsa051203 | Liver | HCC | Epithelial cell signaling in Helicobacter pylori infection | 50/4020 | 70/8465 | 3.96e-05 | 2.16e-04 | 1.20e-04 | 50 |
hsa0516332 | Liver | HCC | Human cytomegalovirus infection | 131/4020 | 225/8465 | 6.86e-04 | 2.77e-03 | 1.54e-03 | 131 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
CXCL1 | CXCR2 | CXCL1_CXCR2 | CXCL | Cervix | ADJ |
CXCL2 | CXCR2 | CXCL2_CXCR2 | CXCL | Cervix | ADJ |
CXCL3 | CXCR2 | CXCL3_CXCR2 | CXCL | Cervix | ADJ |
CXCL8 | CXCR2 | CXCL8_CXCR2 | CXCL | Cervix | ADJ |
CXCL1 | CXCR2 | CXCL1_CXCR2 | CXCL | Cervix | CC |
CXCL2 | CXCR2 | CXCL2_CXCR2 | CXCL | Cervix | CC |
CXCL3 | CXCR2 | CXCL3_CXCR2 | CXCL | Cervix | CC |
CXCL8 | CXCR2 | CXCL8_CXCR2 | CXCL | Cervix | CC |
CXCL1 | CXCR2 | CXCL1_CXCR2 | CXCL | Cervix | Healthy |
CXCL2 | CXCR2 | CXCL2_CXCR2 | CXCL | Cervix | Healthy |
CXCL3 | CXCR2 | CXCL3_CXCR2 | CXCL | Cervix | Healthy |
CXCL8 | CXCR2 | CXCL8_CXCR2 | CXCL | Cervix | Healthy |
CXCL1 | CXCR2 | CXCL1_CXCR2 | CXCL | Cervix | Precancer |
CXCL2 | CXCR2 | CXCL2_CXCR2 | CXCL | Cervix | Precancer |
CXCL3 | CXCR2 | CXCL3_CXCR2 | CXCL | Cervix | Precancer |
CXCL8 | CXCR2 | CXCL8_CXCR2 | CXCL | Cervix | Precancer |
CXCL1 | CXCR2 | CXCL1_CXCR2 | CXCL | Endometrium | EEC |
CXCL2 | CXCR2 | CXCL2_CXCR2 | CXCL | Endometrium | EEC |
CXCL3 | CXCR2 | CXCL3_CXCR2 | CXCL | Endometrium | EEC |
CXCL5 | CXCR2 | CXCL5_CXCR2 | CXCL | Endometrium | EEC |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CXCR2 | SNV | Missense_Mutation | c.985N>A | p.Leu329Ile | p.L329I | P25025 | protein_coding | tolerated(0.06) | benign(0.314) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CXCR2 | SNV | Missense_Mutation | c.787N>C | p.Cys263Arg | p.C263R | P25025 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BS-A0UJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CXCR2 | SNV | Missense_Mutation | rs780840157 | c.239G>A | p.Arg80His | p.R80H | P25025 | protein_coding | tolerated(0.09) | benign(0.173) | TCGA-D1-A15X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CXCR2 | insertion | Frame_Shift_Ins | novel | c.337_338insT | p.Gly115TrpfsTer18 | p.G115Wfs*18 | P25025 | protein_coding | TCGA-AX-A1C4-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
CXCR2 | SNV | Missense_Mutation | c.263T>A | p.Leu88Gln | p.L88Q | P25025 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-UB-A7ME-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
CXCR2 | SNV | Missense_Mutation | novel | c.451G>A | p.Ala151Thr | p.A151T | P25025 | protein_coding | deleterious(0.02) | probably_damaging(0.997) | TCGA-44-6775-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
CXCR2 | SNV | Missense_Mutation | novel | c.997N>T | p.Gly333Cys | p.G333C | P25025 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-49-AARE-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
CXCR2 | SNV | Missense_Mutation | novel | c.856N>C | p.Cys286Arg | p.C286R | P25025 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-64-5781-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
CXCR2 | SNV | Missense_Mutation | c.862N>A | p.Arg288Ser | p.R288S | P25025 | protein_coding | tolerated(0.16) | possibly_damaging(0.898) | TCGA-67-3771-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CXCR2 | SNV | Missense_Mutation | c.754N>T | p.Val252Phe | p.V252F | P25025 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-91-6831-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3579 | CXCR2 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE | agonist | 178100555 | ||
3579 | CXCR2 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE | N-ACETYL-L-CYSTEINE | ACETYLCYSTEINE | 10716998 | |
3579 | CXCR2 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE | agonist | 252166704 | ||
3579 | CXCR2 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE | agonist | 135651724 | ||
3579 | CXCR2 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE | agonist | 178100554 | ||
3579 | CXCR2 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE | antagonist | CHEMBL2103864 | NAVARIXIN | |
3579 | CXCR2 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE | GSK1325756 | DANIRIXIN | ||
3579 | CXCR2 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE | antagonist | 252166707 | ||
3579 | CXCR2 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE | allosteric modulator | 252166706 | REPARIXIN | |
3579 | CXCR2 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE | modulator | CHEMBL189475 | LADARIXIN |
Page: 1 2 3 4 5 |